AgomAb Therapeutics: Building A New Treatment Layer In Fibrosis (NASDAQ:AGMB)
Research and clinical trials
Ontunisertib
Investigational or Emerging
Phase 2 clinical trial
Crohn's disease
Treating fibrotic strictures would address an unmet need in Crohn’s disease — current approved drugs target inflammation, not established fibrosis. Positive Phase 2a signals could eventually lead to a new pharmacologic...